Home › Myelofibrosis › NCT02934477
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Who can join
Ages 55 and older · All sexes
Full eligibility criteria
Inclusion Criteria:
* Patients fulfilling the following criteria will be eligible for inclusion in the study:
* PMF, post-ET MF, or post-PV MF.
* Int-2 or high-risk disease as determined by the DIPSS.
* Age ≥55 at the time of DIPSS assessment.
* For the alloHCT arm:
* Donors must be a 6/6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins) OR an 8/8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donor identified through the National Marrow Donor Program (NMDP)/Be The Match. Donors must meet institutional or NMDP/Be The Match selection criteria; there is no age restriction for sibling donors.
* Both peripheral blood stem cells and bone marrow grafts are allowed.
* All conditioning regimen intensities are allowed.
* All GVHD prophylaxis regimens are allowed.
* Haploidentical donors are allowed in the Haploidentical Donor Study
Exclusion Criteria:
* Patients with the following criteria will be ineligible for entry into the study:
* AlloHCT using umbilical cord blood unit(s) or HLA-mismatched adult donors (\< 6/6 HLA alleles for related and \< 8/8 HLA alleles for unrelated).
* Overlap syndromes.About the study
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
What is being tested
- Hematopoietic Stem Cell Transplant (other)
Sponsor: Center for International Blood and Marrow Transplant Research · Participants: 650 · Started: 2016-11
Contact the study team
- Patricia Steinert, PhD · Phone: 414-805-0700
- Stephanie Farnia · Phone: 763-406-8640
Official record on ClinicalTrials.gov — NCT02934477
Locations in the U.S.
| Minnesota | Center for International Blood and Marrow Transplant Research, Minneapolis |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.